Host Resistance in Relation to Survival in Breast Cancer

Paola, M. Di; Angelini, L.; Bertolotti, A; Colizza, S.

doi:10.1136/bmj.4.5939.268

Cited by 41 publications

(19 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A relationship between host defense mechanisms and prognosis of breast cancer has been discussed for decades (24). In a pioneering study, Aaltomaa and colleagues (19) showed that lymphocytic infiltrates were related to a good outcome in breast cancer, especially in rapidly proliferating tumors.…”

Section: Discussionmentioning

confidence: 99%

The Humoral Immune System Has a Key Prognostic Impact in Node-Negative Breast Cancer

et al. 2008

View full text Add to dashboard Cite

Estrogen receptor (ER) expression and proliferative activity are established prognostic factors in breast cancer. In a search for additional prognostic motifs, we analyzed the gene expression patterns of 200 tumors of patients who were not treated by systemic therapy after surgery using a discovery approach. After performing hierarchical cluster analysis, we identified coregulated genes related to the biological process of proliferation, steroid hormone receptor expression, as well as B-cell and T-cell infiltration. We calculated metagenes as a surrogate for all genes contained within a particular cluster and visualized the relative expression in relation to time to metastasis with principal component analysis. Distinct patterns led to the hypothesis of a prognostic role of the immune system in tumors with high expression of proliferationassociated genes. In multivariate Cox regression analysis, the proliferation metagene showed a significant association with metastasis-free survival of the whole discovery cohort [hazard ratio (HR), 2.20; 95% confidence interval (95% CI), 1.40-3.46]. The B-cell metagene showed additional independent prognostic information in carcinomas with high proliferative activity (HR, 0.66; 95% CI, 0.46-0.97). A prognostic influence of the B-cell metagene was independently confirmed by multivariate analysis in a first validation cohort enriched for high-grade tumors (n = 286; HR, 0.78; 95% CI,) and a second validation cohort enriched for younger patients (n = 302; HR, 0.83; 95% CI, 0.7-0.97). Thus, we could show in three cohorts of untreated, node-negative breast cancer patients that the humoral immune system plays a pivotal role in metastasis-free survival of carcinomas of the breast. [Cancer Res 2008;68(13):5405-13]

show abstract

Section: Discussionmentioning

confidence: 99%

The Humoral Immune System Has a Key Prognostic Impact in Node-Negative Breast Cancer

et al. 2008

View full text Add to dashboard Cite

show abstract

“…It has been possible to enumerate and characterise host cell infiltrates in a number of tumour systems, including melanoma and breast, lung, and gastrointestinal tumours (Gauci and Alexander, 1975;Husby et al, 1976;Ioachim et al, 1976;Lauder et al, 1977). In several turnout types the degree of infiltration has been shown to have a prognostic value (Hamlin, 1968;Bloom et al, 1970;E1-ston and Bagshawe, 1973;Di Paola et al, 1974, 1977Lauder et al, 1977). The implication of such studies is that these features represent an immunological response to the tumour with attraction of reactive cells to the antigenic site, as found in allograft rejection (Tilney and Ford, 1974).…”

Section: Introductionmentioning

confidence: 94%

Cytotoxicity of adherent cells associated with some human tumours and lung tissues

Vose

1978

Cancer Immunol Immunother

View full text Add to dashboard Cite

“…Good prognosis Sistrunk and MacCarty [3] 91 8 Moore and Foote [4] 1000 (449) 5 Richardson [5] 1660 (117) 10 Berg [6] 100 10 Hamlin [7] 272 15 Cutler et al [8] 879 (111) 10 Bloom et al [9] 1411 (104) 20 Ridolfi et al [10] 443 10 DiPaola et al [11] 310 5…”

Section: Authormentioning

confidence: 99%

“…No correlation Griffith et al [12] 77 3 Elston et al [13] 1562 10 Bad prognosis Leitch [14] 5 Months Schumann [15] 11 Months Learmonth [16] 46 5 Lee and Tannenbaum [17] 28 5 Pfahler and Case [18] 15 5 Taylor and Meltzer [19] 38 2 Droulias et al [20] 75 18 Lucas and Perez-Mesa [21] 58 5 Mourali et al [22] 145 NA Levine et al [23] 134 (42) NA Costa et al [24] 94 NA Stewart and Orizaga [25] 56 5 Champion et al [26] 496 6 Morrison et al [27] 253 3 Fisher et al [28] 62 NA Flores et al [29] 95 10 Meyer and Hixon [30] 133 5 Fisher et al [31] 522 5 Fisher et al [32] 522 5 Parkes et al [33] 34 11 Rosen and Groshen [34] 644 18 van Netten et al [35] 25 NA Pupa et al [36] 1200 19…”

Section: Authormentioning

confidence: 99%

See 1 more Smart Citation

The possible role of stromal cell stimulation in worsening the prognosis of a subset of patients with breast cancer

Stewart

Tsai²

1993

Clin Exp Metast

View full text Add to dashboard Cite

This review examines the evidence that a subset of patients with breast cancer have tumors that are stimulated to grow by host cells in the tumor stroma. The search for such a minority group was prompted by the following observations. Adjuvant chemotherapy which is immunosuppressive improves disease-free interval and survival, whereas non-specific immunostimulation worsens the prognosis. Intrinsic immune reactivity is associated with a poor prognosis. A subset of tumors with a bad prognosis has anaplastic cells, dermal lymphatic invasion and a moderate to intense lymphoplasmacytic stromal infiltrate. Evidence is reviewed that adjuvant chemotherapy may be beneficial by virtue of its immunosuppressive effects in addition to tumor kill of minimal residual disease.

show abstract

Host Resistance in Relation to Survival in Breast Cancer

Cited by 41 publications

References 13 publications

The Humoral Immune System Has a Key Prognostic Impact in Node-Negative Breast Cancer

The Humoral Immune System Has a Key Prognostic Impact in Node-Negative Breast Cancer

Cytotoxicity of adherent cells associated with some human tumours and lung tissues

The possible role of stromal cell stimulation in worsening the prognosis of a subset of patients with breast cancer

Contact Info

Product

Resources

About